IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and IMNN-001 Progress

IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing IMNN-001 DNA-mediated IL-12 immunotherapy, will host an R&D Day for investors, analysts and media on Wednesday, September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET. The event will provide an in-depth look at the Company's lead clinical program, IMNN-001, including progress in the pivotal Phase 3 OVATION 3 trial, recent clinical developments and its path forward.

The event will feature presentations from leading oncology experts and IMUNON's management, providing comprehensive updates on the Company's Phase 3 clinical program, evaluating IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer. Discussions will highlight progress and upcoming milestones for the ongoing Phase 3 OVATION 3 clinical trial, as well as insights from the Company's Phase 2 minimal residual disease (MRD) clinical trial conducted in partnership with Break Through Cancer and led by researchers at The University of Texas MD Anderson Cancer Center. The program will also feature a special presentation from a patient treated with IMNN-001, who will share her firsthand perspective on participating in the clinical trial and her treatment journey.

IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON has also reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.

IMNN-001 is designed using IMUNON's proprietary TheraPlas® platform technology. It is an IL-12 DNA plasmid encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local production of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. The Company has also completed dosing in a first-in-human study of its prophylactic vaccine (IMNN-101). Additional details, including the meeting agenda and speaker lineup, will be announced in the coming weeks.